Although there was no statistically significant difference in tumor burden and mice survival between continuous and pulsatile MEK inhibition, the pulsatile group exhibited trends of higher average tumor burden and shorter median survival (49.5 vs 53 days) compared to the continuous group, indicating continuous MEK inhibition is the optimal combination ways of MEKIs and CAR-T cells. This evidence concerns the gene MAP2K7 and neoplasm.